EMEA-000694-PIP01-09-M08 - paediatric investigation plan

dapagliflozin

Key facts

• Invented name:
  Forxiga
• Active Substance:
  dapagliflozin
• Therapeutic area:
  Endocrinology-Gynaecology-Fertility-Metabolism
• Decision number:
  P/0086/2020
• PIP number:
  EMEA-000694-PIP01-09-M08
• Pharmaceutical form(s):
  Film-coated tablet
• Condition(s) / indication(s):
  Treatment of type II diabetes mellitus
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  AstraZeneca AB (Sweden)

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  18/03/2020
• Compliance procedure number:
  EMEA-C-000694-PIP01-09-M08
• Compliance opinion date:
  11/12/2020
• Compliance outcome:
  Positive

Decision

P/0086/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin (Forxiga), (EMEA-000694-PIP01-09-M08)

AdoptedReference Number: EMA/74167/2020